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Abstract
Vaccines are increasingly targeted toward women of reproductive age, and vaccines to prevent 
influenza and pertussis are recommended during pregnancy. Prelicensure clinical trials typically 
have not included pregnant women, and when they are included, trials cannot detect rare events. 
Thus, postmarketing vaccine safety assessments are necessary. However, analysis of observational 
data requires detailed assessment of potential biases. Using data from 8 Vaccine Safety Datalink 
sites in the United States, we analyzed the association of monovalent H1N1 influenza vaccine 
(MIV) during pregnancy with preterm birth (<37 weeks) and small-for-gestational-age birth (birth 
weight < 10th percentile). The cohort included 46,549 pregnancies during 2009–2010 (40% of 
participants received the MIV). We found potential biases in the vaccine–birth outcome 
association that might occur due to variable access to vaccines, the time-dependent nature of 
exposure to vaccination within pregnancy (immortal time bias), and confounding from baseline 
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differences between vaccinated and unvaccinated women. We found a strong protective effect of 
vaccination on preterm birth (relative risk = 0.79, 95% confidence interval: 0.74, 0.85) when we 
ignored potential biases and no effect when accounted for them (relative risk = 0.91; 95% 
confidence interval: 0.83, 1.0). In contrast, we found no important biases in the association of MIV 
with small-for-gestational-age birth. Investigators conducting studies to evaluate birth outcomes 
after maternal vaccination should use statistical approaches to minimize potential biases.
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Large, linked electronic health care data provide the opportunity to study associations 
between exposures (e.g., medications, vaccinations, medical conditions) and pregnancy 
complications (e.g., acute reactions, maternal complications, birth outcomes) within large 
populations without conducting clinical trials. Observational data have been used 
specifically to study the safety of vaccines administered during pregnancy (1–12). Using 
electronic health care data from the Vaccine Safety Datalink (VSD), we evaluated risks of 
acute reactions, maternal medical conditions, and adverse birth outcomes after maternal 
vaccination (7, 10–13).
Previous observational postlicensure studies of vaccine safety or vaccine effectiveness using 
retrospective data have faced challenges. For example, influenza vaccination was found to be 
effective in reducing risk of pneumonia hospitalization and death in elderly patients. 
However, further work revealed that this observation was biased because of differences in 
health-seeking behaviors (14, 15).
In the present paper, we discuss the potential biases in the associations of maternal MIV 
vaccination with preterm and small-for-gestational-age (SGA) births. These biases may 
occur because of limited access to vaccines during the influenza season, referred as cohort 
truncation bias (16, 17); time-dependent exposure of vaccination, referred to as immortal 
time bias (18); and differences in baseline risk factors according to vaccination status. All of 
these biases have not been fully addressed in recent publications (2–5, 8, 19), and Savitz et 
al. (17) recommended re-analyzing data from existing observational studies. We present 
examples of when these biases occur in the VSD pregnancy cohort, propose analytical 
strategies, and demonstrate the effect of ignoring them. Results are presented for the full 
cohort and by trimester of vaccination.
METHODS
Study population
This study was conducted as part of the VSD, a collaboration between the Centers for 
Disease Control and Prevention’s Immunization Safety Office and several integrated health 
care delivery systems. The VSD includes data on 9.5 million subjects, comprising 3% of the 
US population (20). Data for the present study came from 8 VSD sites: Group Health 
Cooperative (Washington), HealthPartners (Minnesota), Kaiser Permanente Colorado 
Vazquez-Benitez et al. Page 2













(Colorado), Kaiser Permanente Northwest (Oregon and Washington), Kaiser Permanente 
Northern California (California), Kaiser Permanente Southern California (California), 
Kaiser Permanente Georgia (Georgia), and Kaiser Permanente Hawaii (Hawaii).
Pregnant women enrolled in VSD sites with a pregnancy end date in 2009–2010 were 
identified using a validated algorithm developed by Hornbrook et al. (21) and adapted and 
validated for use in the VSD by Naleway et al. (22). The algorithm sets the pregnancy start 
date as the date of the woman’s estimated last menstrual period using data from birth 
registries or electronic health records. In order to ensure availability of birth outcome data, 
only pregnancies linked to a livebirth were included. For these analyses, women were 
selected if they were 14–49 years of age at delivery and had a livebirth from January 1, 
2009, to December 31, 2010. To ensure that all pregnancies in 2010 would be captured 
irrespective of their gestational age at delivery, pregnancies with a start date on or after the 
seventh study week of 2010 were excluded. In addition, women were required to have 
continuous enrollment, with no more than a 31-day administrative gap from 6 months before 
pregnancy started through 2 months postpartum and with at least 1 outpatient medical claim 
during pregnancy. We also excluded 1) women who received the MIV within 2 weeks of 
their pregnancy start date or within 1 week of the end of the pregnancy because of 
uncertainty about whether vaccination occurred during pregnancy; 2) women who received a 
live vaccine, which is contraindicated during pregnancy; and 3) women whose pregnancies 
resulted in a gestational duration less than 22 weeks or a birth weight below 500 g, which 
likely representing fetal deaths. Detailed information on exclusions is reported in Web 
Figure 1 (available at http://aje.oxfordjournals.org/).
Identification of exposure
We used the VSD vaccine files to identify whether women had received inactivated MIV, 
trivalent influenza vaccine (TIV), or other vaccines during pregnancy. The period of 
observation included 1 season of H1N1 (2009–2010) and 3 seasons of seasonal influenza 
(2008–2009, 2009–2010, and 2010–2011). The data sources for these files include claims- 
and site-based vaccine registries (20). Workplace or pharmacy vaccination were available 
when manually entered by a health care provider based on patient report or when site-based 
registries were supplemented by state vaccine registries. The recorded date of vaccination is 
accurate (20) except when vaccination was administered during a hospitalization, when it 
may be assigned to the admission date. Timing of vaccination was stratified by pregnancy 
trimester: first trimester was defined as less than 14 weeks’ gestation, second trimester was 
defined as 14–28 weeks’ gestation, and third trimester was defined as 28 weeks’ gestation or 
later. Women who were vaccinated at 37 weeks or later were classified as unvaccinated 
because they were no longer at risk of having a preterm birth.
Outcomes
The 2 primary outcomes were preterm birth and SGA birth. Preterm birth was defined as 
delivery from 22 to 37 weeks’ gestation, and SGA birth was defined as a birth weight less 
than the 10th percentile for a given gestational age, based on national averages. Gestational 
age corresponds to the clinical estimate of gestational age. Weights for gestational age 
percentiles were obtained from Oken et al. (23). Their work provides comprehensive 
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reference values for distributions of birth weights at 22–44 completed weeks of gestation 
that were derived from broadly based nationwide data and stratified by sex. Previous work 
has shown data captured in electronic health records and birth registries to be adequate: 
Through chart review, 94% were confirmed to have gestational ages within 14 days of the 
reference values, and 99% were confirmed as having low birth weight (less than 2,500 g) 
(24).
Baseline risk factors
Markers for high-risk pregnancies included pre-existing hypertension, diabetes, 
cardiovascular disease, and renal disease. These conditions were identified from inpatient 
and outpatient International Classification of Diseases, Ninth Revision, codes in electronic 
health care data starting 6 months before pregnancy and continuing through the end of the 
pregnancy. Health care utilization variables included receipt of medical care in the first 
trimester, the Kotelchuck Adequacy of Prenatal Care Utilization Index derived from VSD 
data (25, 26), and the number of hospitalizations during the first 20 weeks of pregnancy. 
Sociodemographic variables included race/ethnicity, maternal age at date of delivery, and 
census tract poverty level, which was defined for each subject as the percent of families in 
their census tract with an income below 150% of the federal poverty level. When a maternal 
address was missing (7%), data on poverty were imputed using the expectation 
maximization model algorithm that included health care utilization variables (27). Periods of 
influenza circulation were derived from FluNet data for 2009–2010 (28).
Analysis
We performed 3 analyses. First, we identified periods during 2009 and 2010 when pregnant 
women had access to vaccination or were exposed to influenza circulation. Second, we 
evaluated whether baseline risk factors during pregnancy were associated with vaccination. 
Third, we performed a sensitivity analysis in which we incorporated several strategies to 
account for potential biases in the vaccine–birth outcome associations.
To identify the period when women had no access to vaccination (MIV or TIV), we plotted 
the distribution of pregnancies according to study week of vaccination, pregnancy start 
week, and delivery week according to vaccination status and pregnancy trimester of 
vaccination. Weeks of the 2 calendar years 2009 and 2010 were combined and counted 
sequentially, and the weeks of the study were numbered. For example, the week of January 
1, 2009, corresponded to week 0, and the week of February 13, 2010, corresponded to week 
58.
To evaluate whether baseline characteristics were associated with vaccine exposure, we 
estimated the standardized difference (difference between means divided by the pooled 
standard deviation). This measure is insensitive to sample size. A standardized difference of 
0.2 or greater in absolute value is considered a large imbalance, and above 0.1 is considered 
meaningful (29). Data on other potential confounders, such as parity, smoking, and alcohol 
use, were not available in VSD files.
We used a propensity adjustment approach to evaluate the potential confounding from 
baseline characteristics in the association between MIV receipt and birth outcome. To 
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construct the propensity score, the following covariates were included: sociodemographic 
variables, VSD site, presence of medical conditions, and health utilization variables. We 
used a generalized additive model with a smooth parameter for maternal age and study week 
of last menstrual period to adequately capture the nonlinear associations. Model fit was 
evaluated using the C statistic and Hosmer-Lemeshow goodness-of-fit test.
To demonstrate the effect of ignoring potential biases when evaluating maternal vaccination 
and birth outcomes, we performed a sensitivity analysis. Analyses were performed for the 
full cohort and stratified by trimester of vaccination. We used 5 stepwise approaches to 
evaluate associations between maternal vaccination and birth outcomes. In the first, we 
ignored all potential biases (naïve approach) and used a Cox regression model to estimate 
the associations. In the case of the vaccine–preterm birth association in the first trimester or 
vaccine–SGA birth association during any point in pregnancy, this method is equivalent to a 
non-censored approach, and the estimates correspond to risk ratios. In the second, we 
accounted for time-dependent vaccine exposure within pregnancy (immortal time bias) using 
a time-dependent covariate Cox model. In the third, in addition to step 2, we excluded 
pregnancies having no access to MIV vaccination. 4) In addition to the factors in model 3, 
we added the propensity score to the model to account for potential imbalance of baseline 
risk factors. Finally, the fifth model, we used model 4 and added H1N1 circulation as a time-
dependent confounder. Measures of association are presented with 95% confidence intervals. 
Analyses were performed using SAS/STAT, version 9.3 (SAS Institute, Inc., Cary, North 
Carolina). This study was approved by the institutional review boards at all participating 
sites and the Centers for Disease Control and Prevention.
RESULTS
Figure 1 presents histograms of study week during which vaccination occurred according to 
trimester of vaccination and vaccine type (MIV or TIV). These histograms show that access 
to MIV and TIV vaccination differed by pregnancy trimester and that the likelihood of 
vaccination depended on the study week. In all pregnancy trimesters, MIV was more likely 
to be given in the first weeks of the vaccination season. The distribution of study week for 
TIV reflects the 3 vaccination seasons captured in our cohort (2008–2009, 2009–2010, and 
2010–11). Vaccination periods for TIV and MIV and H1N1 circulating periods are available 
in Web Table 1.
Figure 2 presents histograms of study week at pregnancy start date according to vaccination 
status, trimester of vaccination, and type of vaccine (MIV or TIV). The distribution of study 
week at pregnancy start date in unvaccinated women was relatively uniform; women 
received MIV only in the first trimester when the pregnancy start date occurred after study 
week 25. Similarly, women received MIV in the second trimester when the pregnancy start 
date occurred after study week 11.
Figure 3 presents histograms of study week at pregnancy end date according to vaccination 
status, trimester of vaccination, and type of vaccine (MIV or TIV). In this case, because 
MIV was available after study week 37, women who had pregnancies with an end date 
before study week 38 had no access to vaccine during pregnancy. Thus, in pregnancies with 
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a start date that occurred in early 2009, vaccination was more likely for those with longer 
gestational period. We classified the period for having no access to vaccination as a 
pregnancy start date before study week 12. This group represented 20% of the cohort.
Likelihood of vaccination due to baseline risk factors
Moderate imbalances in health care utilization, race/ethnicity, and residing in areas with an 
elevated poverty level (standardized difference > 0.1) by vaccination status were observed. 
In addition, there was a large imbalance for receipt of TIV and study week at last menstrual 
period (standardized difference > 0.2) (Table 1)
Model fit of the propensity score had a C statistic = 0.77 and a P value < 0.00001 (8 df) for 
the Hosmer-Lemeshow test. Nonlinear associations were corroborated by the smoothing 
component (partial prediction) plots for maternal age at the end of pregnancy and pregnancy 
start week (Web Figure 2). When ignoring study week during which pregnancy started, 
propensity score properties were poor (C statistic = 0.58), confirming that most of the 
likelihood of MIV receipt is driven by the temporal availability of the vaccine.
Sensitivity analyses to evaluate potential bias of the MIV–birth outcome association
The crude prevalence rates of preterm birth (less than 37 weeks) and SGA birth (<10th 
percentile) by receipt of MIV and trimester of vaccination are presented in Table 2. SGA 
birth rates had small variations ranging from 7.5 to 8.9. In contrast, rates of preterm birth 
varied widely, from 8.2 for those who did not receive MIV to 4.2 in those who were 
vaccinated in the third trimester.
Table 3 presents the results of sensitivity analyses of the MIV–birth outcome associations for 
the full cohort and by trimester of vaccination. For the MIV–preterm birth association in the 
full cohort, the naïve model indicated a protective effect (relative risk (RR) = 0.79; 95% 
confidence interval (CI): 0.74, 0.85; model 1). This protective effect was diluted when 
accounting for the time-dependent MIV exposure (RR = 0.88; 95% CI: 0.82, 0.94; model 2). 
After pregnancies in which the mothers had no access to vaccination were excluded, the 
relative risk was 0.91 (95% CI: 0.84, 0.98; model 3). Further adjustment by propensity score 
and accounting for H1N1 circulation resulted in a null association (RR = 0.91; 95% CI: 
0.83, 1.0; model 5). Analyses specific to first and second trimester vaccination showed a 
protective effect when we ignored all potential biases (in model 1, for the first trimester, RR 
= 0.85, 95% CI: 0.77, 0.93; for the second trimester, RR = 0.87, 95% CI: 0.79, 0.95). When 
women with no access to vaccination were removed from the analyses, the protective effect 
was diluted (in model 3, for the first trimester, RR = 0.88, 95% CI: 0.79, 0.98; for the second 
trimester, RR = 0.90; 95% CI: 0.80, 1.01). Further adjustment for propensity to vaccination 
or H1N1 circulation did not affect the results (models 4 and 5). For third trimester 
vaccination, the time-dependent nature of exposure and access to vaccination affected the 
association estimate (in model 1, RR = 0.63, 95% CI: 0.55, 0.72; in model 3, RR = 0.97, 
95% CI: 0.82, 1.14). Adjustment for propensity to be vaccinated and H1N1 circulation did 
not modify the association (in model 5, RR = 1.0, 95% CI: 0.83, 1.20). MIV–preterm birth 
associations were consistent in all 3 trimesters when we accounted for all potential biases.
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The MIV–SGA birth associations were consistent across all approaches. The risk of SGA 
birth was not higher after MIV vaccination during any point in pregnancy (in model 1, RR = 
0.97, 95% CI: 0.91, 1.03; in model 5, RR = 1.0, 95% CI: 0.93, 1.08). Null results were 
observed for vaccination in the second and third trimesters. A weak protective effect was 
observed for first trimester vaccination (in model 5, RR = 0.90, 95% CI: 0.82, 0.99).
DISCUSSION
In the present retrospective cohort study, we demonstrated that ignoring potential biases can 
strongly affect the observed MIV–preterm birth associations but not MIV–SGA birth 
associations. Sources of bias in the MIV–preterm birth association depended strongly on the 
seasonality or timing of the start of pregnancy and the immortal time bias. When women 
were stratified according to vaccination status, the baseline characteristics addressed in these 
analyses were similar or had only small imbalances, except for pregnancy start week. Our 
results that were based on the fully adjusted models did not indicate an association of 
maternal receipt of MIV with preterm birth; only first trimester vaccination showed an 
association. An MIV–SGA association was not observed for the full cohort, but again, an 
association was observed in the first trimester.
Our results are consistent with those from previous studies (7, 30). In a meta-analysis of 
seasonal and H1N1 vaccines, no evidence of harmful effects with regard to preterm birth 
was found (7, 30). Seven studies (1, 2, 4, 5, 8, 19, 31) indicated a statistically strong 
protective effect for preterm birth, defined as less than 37 weeks gestation, after vaccination. 
The protective effect ranged from a relative risk of 0.40 to a relative risk of 0.86. There were 
no studies in which maternal vaccination was found to be associated with SGA birth. Of the 
studies in which results were presented by trimester of vaccination, there were none in 
which investigators found an association with preterm birth in the first trimester; however, a 
protective association in the third trimester was found in 1 study (8).
Our study complements the work presented by Fell et al. (30). Fell et al. reviewed the design 
heterogeneity (study design and analytical approach) of published articles on the association 
between vaccinations and preterm birth. In the present study, we addressed several of the 
potential biases that can be introduced when analyzing that association. For example, 
focusing on conventional methods, such as multivariable adjustment, propensity methods, 
matching, or exclusion of women who have rare exposure to risk factors, may not be 
sufficient to address other potential biases, such as access to vaccination, seasonal 
confounding, and immortal time bias.
There have been a number of studies in which researchers have addressed access to 
vaccination resulting in a cohort truncation bias (16, 17). The approaches used included 
having access to vaccination in the third trimester (2); having access to vaccination for each 
trimester (6, 7, 31); having a prenatal care visit during the vaccination period (33); or 
matching or stratifying by date of birth (1, 34, 35). However, methods that accounted only 
for the date of birth may not fully control for differential access to vaccination for preterm 
birth, because a longer pregnancy length is associated with having more opportunities to be 
vaccinated. Our present study included detailed analyses to identify calendar periods during 
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which access to vaccination posed a threat to the validity of the results. Only pregnant 
women with longer gestational age would have been vaccinated in the early weeks of the 
vaccination campaign in 2009, which would have primarily affected maternal vaccination in 
the third trimester.
Seasonal confounding has been identified as a potential source of bias in studies of the 
associations of exposures with birth outcomes, with the rate of prematurity and birth weight 
being dependent on season of conception (36, 37), although this potential bias may be only 
an artifact of the cohort truncation bias. Therefore, grouping pregnancies by pregnancy start 
date, care date, or trimester of vaccination may account for the 2 potential biases 
simultaneously. Xu et al. (38) suggested the incorporation of other time-dependent 
confounders through a time-dependent Cox model. In our analysis, in addition to addressing 
the cohort truncation bias, we incorporated H1N1 circulation as a time-dependent covariate 
and found that our results were not affected. In our analysis, we did not adjust for receipt of 
TIV because the differential access to TIV observed in our study period may have 
introduced further bias, as there was little overlap in the periods when both vaccines were 
available.
Bias introduced by time-dependent exposure in analyses of preterm birth outcomes has been 
widely documented (18, 39–41). Time-dependent exposure was addressed in several but not 
all prior studies. Several studies lacked the date of vaccination (3, 4), had incomplete capture 
of vaccination date (8, 42), or used self-reported data (5, 19). In most studies in which the 
vaccination dates were available, investigators censored the vaccination exposure (6–8, 31, 
42, 43), and only in a few studies was a time-dependent covariate method used to analyze 
the vaccine–preterm birth association (5, 34, 43). In other studies, researchers used stratified 
methods to compare with unvaccinated women who had not given birth (8, 44, 45) or 
included an interaction term for date of delivery (31).
Methods used to limit the effect of potential confounding because of imbalance of risk 
factors included exclusions of some subgroups and adjustment methods. Exclusions 
identified are multiple livebirths, not receiving prenatal care, exposure to H1N1, or having 
received treatment for influenza. Prior studies have included sociodemographic factors, the 
presence of comorbid conditions, behavioral factors, and other pregnancy-related 
characteristics as potential confounders. In terms of methods used for adjustment, studies 
have included multivariable adjustment (1, 2, 5, 19, 31, 33, 43, 45, 46), stratified approaches 
(8), propensity score adjustment (32, 34, 42), propensity score matching (2, 3, 6, 7), or other 
matching strategies (47). In most cases, when studies results were reported as crude and 
adjusted associations, results were similar (31, 33). In studies in which results based on 
different adjustment approaches were compared, no differences in associations were found 
(2, 5). In the present study, we found few covariates that were associated with MIV status. 
The only variable driving the performance of the propensity score was calendar date of last 
menstrual period. Thus, our results are consistent with other studies, indicating a minor 
concern for confounding by indication, which likely reflects the routine recommendation of 
vaccination during pregnancy during the period of observation (48).
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Our study had some limitations. We did not have access to data on several potential 
confounders, such as smoking, parity, and prior history of preterm birth. We incorporated a 
broad number of conditions into the propensity to vaccination variable, some of which had a 
weak association with the birth outcomes presented (49). However, propensity approaches 
are appropriate for handling a larger number of potential confounders (50). Our cohort was 
limited to women with continuous insurance coverage and at least 1 outpatient encounter. 
Thus, women with no insurance or interrupted coverage were underrepresented. Our cohort 
excluded pregnancies for which no birth outcomes were available. Most of these pregnancies 
correspond to the 1-year lag in birth registries. Data on vaccination date have been shown to 
be accurate (20), but women who were vaccinated at alternate sites might have been 
misclassified in our cohort. Although our data relied heavily on automated electronic health 
record data and birth registries for assigning gestational age at delivery and birth weight, 
these sources of data in our systems have been found to be valid (24). Accuracy of clinical 
estimate of gestational age in this population may be explained by the wide access to 
ultrasound data in addition to the results of newborn examination (51). Finally, our analyses 
were restricted to livebirths, and thus we were unable to evaluate whether the exclusion of 
stillbirth affected the observed maternal MIV–birth outcome associations.
Conclusions
Our results are consistent with those from other studies in which investigators found no 
increased risk of preterm or SGA birth after maternal H1N1 vaccination. Our analyses 
demonstrated that the apparent protective effects observed in several studies of the 
association between influenza vaccination and preterm birth were attenuated when we 
accounted for temporal confounders. Further studies using retrospective cohorts analyzing 
vaccine–birth outcome associations may benefit by incorporating the analytical techniques 
that we utilized to minimize these potential biases.
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Histograms of study week during which vaccination occurred according to trimester of 
vaccination and type of vaccine (monovalent or trivalent), Vaccine Safety Datalink Cohort, 
2009–2010. A) Monovalent influenza vaccine (MIV) in the first trimester; B) MIV in the 
second trimester; C) MIV in the third trimester; D) trivalent influenza vaccine (TIV) in the 
first trimester; E) TIV in the second trimester; and F) TIV in the third trimester.
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Histograms of study week of last menstrual period (LMP) date according to vaccination 
status, trimester of vaccination, and type of influenza vaccine (monovalent or trivalent), 
Vaccine Safety Datalink Cohort, 2009–2010. A) Not vaccinated with monovalent influenza 
vaccine (MIV); B) MIV in first the trimester; C) MIV in second the trimester; D) MIV in 
third the trimester; E) not vaccinated with trivalent influenza vaccine (TIV); F) TIV in first 
the trimester; G) TIV in second the trimester; and H) TIV in third the trimester.
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Histograms of study week during which delivery occurred according to vaccination status, 
trimester of vaccination, and type of influenza vaccine (monovalent or trivalent), Vaccine 
Safety Datalink Cohort, 2009–2010. A) Not vaccinated with monovalent influenza vaccine 
(MIV); B) MIV in first the trimester; C) MIV in second the trimester; D) MIV in third the 
trimester; E) not vaccinated with trivalent influenza vaccine (TIV); F) TIV in first the 
trimester; G) TIV in second the trimester; and H) TIV in third the trimester.
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Table 2
Crude Prevalence Rates (per 100 Births) of Preterm and Small-for-Gestational-Age Births Among Study 
Participants (n = 46,549) by Monovalent Influenza Vaccine Status, Vaccine Safety Datalink Cohort, 2009–
2010
MIV Status No. of Pregnancies SGA Birth (<10th Percentile) Preterm Birth (<37 Weeks)
No MIV 27,392 8.6 8.2
Received MIV
 Any time during pregnancy 19,157 8.3 6.1
 First trimester 6,788 7.5 6.8
 Second trimester 7,096 8.9 6.9
 Third trimester 5,244 8.5 4.2
Abbreviations: MIV, monovalent influenza vaccine; SGA, small-for-gestational-age.
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